Aegis Affirms Medivation (MDVN) at 'Buy'; Comments on Recent XTANDI Approval
Tweet Send to a Friend
Aegis Capital affirms Medivation, Inc. (Nasdaq; MDVN) at Buy with a price target of $130 after the FDA recently approved ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
